住院急性肾损伤患者的早期个体化建议:一项随机临床试验
这项在7家医院开展的随机临床试验纳入4003例住院AKI患者,干预组由肾脏行动团队在检测到AKI后1小时内通过电子病历发送涵盖诊断检查、容量、钾、酸碱和药物五大类的个体化建议,对照组接受常规治疗。主要复合终点(AKI进展至更高分期、透析或住院期间14天内死亡)在干预组为19.8%,对照组为18.4%(差异1.4%,95%CI -1.1%至3.8%,P=0.28),无显著差异。6个次要终点中仅建议执行率有显著差异:干预组24小时内执行2459/7270条(33.8%),对照组1766/7269条未送达建议(24.3%)(差异9.5%,95%CI 8.1%至11.0%)。作者结论认为,尽管建议执行率更高,该干预未能显著改善复合终点。
要点
- 主要复合终点(AKI进展、透析或14天内死亡)干预组19.8% vs 常规组18.4%,差异1.4%(95%CI -1.1%至3.8%,P=0.28),无显著差异。
- 肾脏行动团队共发出14539条建议,每例患者中位数3条(IQR 2-5),建议涵盖诊断检查、容量、钾、酸碱和药物五大类。
- 干预组24小时内建议执行率33.8%(2459/7270)vs 常规组未送达建议执行率24.3%(1766/7269),差异9.5%(95%CI 8.1%至11.0%)。
- 6个次要终点中仅建议执行率有显著差异,其余次要终点两组间无显著差异。
- 研究在2个卫生系统的7家医院开展,共随机4003例患者,中位年龄72岁(IQR 61-81),女性1874例(47%),黑人患者931例(23%)。
适用人群与场景
- 住院期间发生急性肾损伤(AKI)的成人患者,随机化于2021年10月29日至2024年2月8日进行,最终随访至2024年2月22日。
- 研究场所为2个卫生系统的7家医院:康涅狄格州纽黑文、布里奇波特、新伦敦、沃特伯里,罗德岛州韦斯特利,以及马里兰州巴尔的摩。
处置流程与药物剂量
- 检测到AKI后1小时内,由研究医师和研究药师组成的肾脏行动团队通过电子病历发送个体化建议,涵盖诊断检查、容量、钾、酸碱和药物五大类。
- 建议生成后对患者进行随机化,仅干预组患者的临床医生可看到建议;对照组接受常规治疗。
研究设计与关键结果
- 随机对照试验,纳入4003例住院AKI患者(中位年龄72岁,IQR 61-81;女性1874例,47%;黑人931例,23%),干预组接受肾脏行动团队通过电子病历发送的个体化建议,对照组接受常规治疗。
- 主要复合终点(AKI进展至更高分期、透析或住院期间14天内死亡)干预组19.8% vs 对照组18.4%,差异1.4%(95%CI -1.1%至3.8%,P=0.28),无显著差异。
- 6个次要终点中仅建议执行率有显著差异:干预组24小时内执行2459/7270条(33.8%),对照组1766/7269条未送达建议(24.3%),差异9.5%(95%CI 8.1%至11.0%)。
- 肾脏行动团队共发出14539条建议,每例患者中位数3条(IQR 2-5)。
证据类型、等级与局限
- 随机临床试验(RCT),在7家医院开展,样本量4003例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于住院AKI患者,由肾脏行动团队通过电子病历发送早期个体化建议虽可提高建议执行率(33.8% vs 24.3%,差异9.5%,95%CI 8.1%至11.0%),但未显著降低AKI进展至更高分期、透析或14天内死亡的复合终点(19.8% vs 18.4%,P=0.28)。
指南或共识出处
- 试验注册号:ClinicalTrials.gov NCT04040296。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acute kidney injury (AKI) is a common complication during hospitalization and is associated with adverse outcomes.
OBJECTIVE: To evaluate whether diagnostic and therapeutic recommendations sent by a kidney action team through the electronic health record improve outcomes among patients hospitalized with AKI compared with usual care.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 7 hospitals in 2 health systems: in New Haven, Bridgeport, New London, and Waterbury, Connecticut, and Westerly, Rhode Island; and in Baltimore, Maryland. Hospitalized patients with AKI were randomized between October 29, 2021, and February 8, 2024. Final follow-up occurred February 22, 2024.
INTERVENTION: An alert about AKI was sent to the kidney action team, consisting of a study physician and study pharmacist, which sent personalized recommendations through the electronic health record in 5 major categories (diagnostic testing, volume, potassium, acid base, and medications) within 1 hour of AKI detection. The note was immediately visible to anyone with access to the electronic health record. Randomization to the intervention or usual care occurred after the recommendations were generated, but the note was only delivered to clinicians of patients randomized to the intervention group.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite outcome consisting of AKI progression to a higher stage of AKI, dialysis, or mortality occurring while the patient remained hospitalized and within 14 days from randomization.
RESULTS: Of the 4003 patients randomized (median age, 72 years [IQR, 61-81 years), 1874 (47%) were female and 931 (23%) were Black patients. The kidney action team made 14 539 recommendations, with a median of 3 (IQR, 2-5) per patient. The primary outcome occurred in 19.8% of the intervention group and in 18.4% in the usual care group (difference, 1.4%, 95% CI, -1.1% to 3.8,% P = .28). Of 6 secondary outcomes, only 1 secondary outcome, rates of recommendation implementation, significantly differed between the 2 groups: 2459 of 7270 recommendations (33.8%) were implemented in the intervention group and 1766 of 7269 undelivered recommendations (24.3%) were implemented in the usual care group within 24 hours (difference, 9.5%; 95% CI, 8.1% to 11.0%).
CONCLUSIONS AND RELEVANCE: Among patients hospitalized with AKI, recommendations from a kidney action team did not significantly reduce the composite outcome of worsening AKI stage, dialysis, or mortality, despite a higher rate of recommendation implementation in the intervention group than in the usual care group.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04040296.
参考来源
- Aklilu AM, Menez S, Baker ML, et al. Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2024. PMID: 39454050. doi:10.1001/jama.2024.22718
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。